

Cervical HPV mRNA Testing Market Outlook 2026–2030: Growth Trends, Innovations & Key Developments

The Business Research Company's Cervical HPV mRNA Testing Market Outlook 2026–2030: Growth Trends, Innovations & Key Developments

LONDON, GREATER LONDON, UNITED KINGDOM, March 1, 2026

[/Einpresswire.com/](https://www.einpresswire.com/) -- "The cervical human papillomavirus (HPV)

messenger ribonucleic acid (mRNA) testing market is emerging as a vital component in the fight against cervical cancer, with its rapid advancements and expanding applications. This diagnostic approach is gaining traction due to its specificity and the growing demand for more accurate screening methods. Below, we explore the market's size, growth drivers, regional outlook, and technological trends shaping its future.



Expected to grow to \$2.12 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%"

The Business Research Company

Strong Growth Trajectory in the Cervical HPV mRNA Testing Market Size

The cervical HPV mRNA testing market has experienced significant expansion recently. Market value is projected to rise from \$1.06 billion in 2025 to \$1.22 billion by 2026, reflecting a robust compound annual growth rate (CAGR) of 14.6%. This historic growth has been driven by wider

cervical cancer screening programs, the increased use of molecular diagnostics in gynecological care, heightened awareness of high-risk HPV infection dangers, availability of automated PCR platforms, and the growth of centralized diagnostic labs.

Download a free sample of the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33060&type=smp&utm_source=EinPresswire&utm_medium=Paid&utm_campaign=Feb_PR

Future Projections Signal Continued Expansion of the Cervical HPV mRNA Testing Market



Looking ahead, the cervical HPV mRNA testing market is forecasted to grow even faster, reaching \$2.12 billion by 2030 with a CAGR of 14.9%. This surge is expected to be fueled by a greater shift towards using primary HPV screening, rising demand for highly specific cancer risk stratification tools, broader population-based screening initiatives, integration of digital pathology and reporting systems, and increased investments in precision diagnostics. Key trends anticipated include more widespread adoption of mRNA-based primary cervical screening assays, enhanced use of fully automated molecular testing platforms, incorporation of genotype-specific reflex testing, expansion of high-specificity screening algorithms, and a stronger focus on clinically actionable HPV detection.

Understanding Cervical HPV mRNA Testing and Its Clinical Significance

Cervical HPV mRNA testing is a molecular diagnostic technique that identifies the presence of E6/E7 oncogenic mRNA transcripts from high-risk HPV types in cervical samples. This method detects active viral infections that contribute to cervical cell transformation, providing more specific information compared to traditional HPV DNA tests, which only reveal the presence of viral genetic material. By targeting mRNA expression, this testing approach offers better clinical relevance for identifying infections linked to a higher risk of cervical precancer and cervical cancer.

View the full cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market report:

https://www.thebusinessresearchcompany.com/report/cervical-human-papillomavirus-hpv-messenger-ribonucleic-acid-mrna-testing-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Feb_PR

Rising Cervical Cancer Cases as a Primary Driver for Market Growth

The increasing incidence of cervical cancer is a key factor propelling the cervical HPV mRNA testing market forward. Cervical cancer, a malignancy originating in cervical cells, is primarily caused by persistent infection with high-risk HPV types and remains a major cause of cancer-related morbidity and mortality among women globally. Low participation in cervical screening programs leads to delayed diagnosis and progression of HPV infections into cancer. The use of cervical HPV mRNA testing supports early detection of active high-risk HPV infections, improves risk stratification, and facilitates timely medical intervention to prevent cancer progression. For example, according to Cancer Australia, there were 265 cervical cancer deaths in 2023, with an estimated 254 deaths expected in 2025, underscoring the ongoing health burden and need for effective diagnostic tools.

Geographical Distribution Highlights North America's Market Lead

In 2025, North America held the largest share of the cervical HPV mRNA testing market, demonstrating its leadership in adopting advanced molecular diagnostics. Meanwhile, the Asia-Pacific region is poised to experience the fastest growth during the forecast period. The market analysis covers several key regions, including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a broad

perspective on global market dynamics.

Browse Through More Reports Similar to the Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market 2026, By The Business Research Company

HPV testing and Pap test global market report

<https://www.thebusinessresearchcompany.com/report/hpv-testing-and-pap-test-global-market-report>

HPV associated disorders global market report

<https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report>

human papillomavirus HPV vaccine global market report

<https://www.thebusinessresearchcompany.com/report/human-papillomavirus-hpv-vaccine-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company -

https://www.thebusinessresearchcompany.com/?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=home_page_test

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/896099300>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.